Clinical trials: Advanced RCC
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with…
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck
- Trial name
- NCT04504669
- Testing
- AZD8701, Durvalumab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Renal Cell Carcinoma
A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma
This study is being conducted to determine the Maximum Tolerated Dose (MTD) and efficacy of the combined treatment of Temsirolimus and Sunitinib for the treatment of Advanced Kidney Cancer
- Trial name
- NCT00417677
- Testing
- Combination of Temsirolimus and Sunitinib
- Where
- 4 sites in United States
- Volunteers
- 124 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Renal Cell Carcinoma
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer.
- Trial name
- NCT06699602
- Testing
- Cemiplimab, Fianlimab
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
- Trial name
- NCT01115803
- Testing
- LY2584702, Erlotinib, Everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Therapeutic Patient Education, Immune Checkpoint Inhibitors
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology
The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI
- Conditions
- Therapeutic Patient Education, Immune Checkpoint Inhibitors, Melanoma, Advanced Non-small Cell Lung Cancer
- Trial name
- EDHITO (NCT03948724)
- Testing
- Therapeutic education program, Usual Information
- Where
- 9 sites in France
- Volunteers
- 412 people
- Sponsor
- Institut Cancerologie de l'Ouest
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
This phase II trial tests adding VSV-IFNβ-NIS to standard of care ipilimumab and nivolumab for the treatment of clear cell renal cell carcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT07510334
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer, Non-Small Cell Lung Cancer
Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment
A multi-center, open-label, extended treatment, clinical trial examining the safety of administering multiple does of panitumumab by intravenous (i.v.) infusion to patients who have previously received panitumumab and benefited…
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Solid Tumors
- Trial name
- NCT00425204
- Testing
- Panitumumab (ABX-EGF)
- Volunteers
- 31 people
- Sponsor
- Amgen
Renal Cell Carcinoma, Kidney Cancer
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
The purpose of this study is to investigate the safety and feasibility of administering investigational drugs (meaning not Food and Drug Administration (FDA)-approved for kidney cancer) prior to surgical treatment for kidney…
- Trial name
- NCT02762006
- Testing
- Durvalumab, Tremelimumab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Moshe Ornstein
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors, Solid Tumor
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors
- Conditions
- Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult
- Trial name
- NCT02974738
- Testing
- Belzutifan
- Volunteers
- 120 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Advanced Renal Cell Carcinoma
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
Phase I / II, open, prospective, multicenter single-arm, Clinical Trial in two stages: in the first stage it will determine the optimal dose of the combination of pazopanib and interferon alfa-A2 in the treatment of patients with…
- Trial name
- NCT01513187
- Testing
- Pazopanib + interferon alpha 2A
- Where
- 13 sites in Spain
- Volunteers
- 53 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Kidney Cancer
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Sunitinib and erlotinib may stop the growth of tumor cell by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00425386
- Testing
- erlotinib hydrochloride, sunitinib malate, biopsy
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- OHSU Knight Cancer Institute
Kidney Cancer
Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interferon alfa use different ways to stimulate the immune system and stop…
- Trial name
- NCT00045370
- Testing
- recombinant interferon alfa, temsirolimus
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Renal Cell Carcinoma
Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2
Multicenter, 2-part, multiple-dose study designed to evaluate the safety and effectiveness of weekly administration of panitumumab in subjects with renal carcinoma. Part 1 was initiated in 2001 and will not be presented here.
- Trial name
- NCT00425035
- Testing
- Panitumumab (ABX-EGF)
- Volunteers
- 115 people
- Sponsor
- Amgen
Renal Cell Carcinoma
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles, and preliminary efficacy of belzutifan as monotherapy followed by belzutifan+lenvatinib combination therapy, as well…
- Trial name
- NCT05030506
- Testing
- Belzutifan, Pembrolizumab, Lenvatinib
- Where
- 5 sites in China
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Advanced/Metastasis Renal Cell Carcinoma
A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients
INVESTIGATIONAL PRODUCT: TLC388 (Lipotecan*) *Lipotecan is a drug product of TLC388 HCl. PHASE OF DEVELOPMENT: Phase II No. OF PATIENTS: Approximately 40 (Stage I: 15 evaluable patients, Stage II: 25 evaluable patients) STUDY…
- Trial name
- NCT01831973
- Testing
- Lipotecan
- Where
- 5 sites in Taiwan
- Volunteers
- 18 people
- Sponsor
- Taiwan Liposome Company
Kidney Cancer
Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced kidney cancer.
- Trial name
- NCT00004880
- Testing
- dendritic cell vaccine therapy, conventional surgery
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center